Code intelligence

FDA-BLA761166 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance referencing code FDA-BLA761166.

Critical code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Critical

Critical

100%

High

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: BESREMI (ROPEGINTERFERON ALFA-2B) — Type 1 - New Molecular Entity

Policy FDA-BLA761166 · Hematology

Critical

Besremi (ropeginterferon alfa-2b) is a subcutaneously administered injectable approved for polycythemia vera, supporting a Part B billing pathway as a physician-administered drug. As an orphan drug in

View alert